HUTCHMED (00013) Holds Investor Meeting to Share Latest R&D Progress and Pipeline Updates

Stock News

10 hours ago

HUTCHMED (00013) announced key updates on its research and business developments during an investor meeting held on October 31, 2025. The event highlighted the company's advancements in innovative therapies for cancer and immune-related diseases, including its next-generation Antibody Targeted Therapeutics Conjugate (ATTC) platform and progress in late-stage pipeline candidates.

Dr. Shi Ming, Chief Medical Officer and Head of R&D at HUTCHMED, stated, "Addressing critical unmet medical needs in oncology and immunology remains central to HUTCHMED's mission, driving our commitment to pioneering novel treatments. The ATTC platform has the potential to redefine precision cancer therapy, and with our robust pipeline and collaborative strategy, we are confident in delivering potentially transformative therapies for patients worldwide."

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1174885812"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1174885812\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1174885812?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-03 08:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1174885812","market":"sg","top_or_hot":-1,"title":"HUTCHMED (00013) Holds Investor Meeting to Share Latest R&D Progress and Pipeline Updates","media":"Stock News","content":"<p>HUTCHMED (00013) announced key updates on its research and business developments during an investor meeting held on October 31, 2025. The event highlighted the company's advancements in innovative therapies for cancer and immune-related diseases, including its next-generation Antibody Targeted Therapeutics Conjugate (ATTC) platform and progress in late-stage pipeline candidates.</p>\n<p>Dr. Shi Ming, Chief Medical Officer and Head of R&D at HUTCHMED, stated, \"Addressing critical unmet medical needs in oncology and immunology remains central to HUTCHMED's mission, driving our commitment to pioneering novel treatments. The ATTC platform has the potential to redefine precision cancer therapy, and with our robust pipeline and collaborative strategy, we are confident in delivering potentially transformative therapies for patients worldwide.\"</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HUTCHMED (00013) Holds Investor Meeting to Share Latest R&D Progress and Pipeline Updates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHUTCHMED (00013) Holds Investor Meeting to Share Latest R&D Progress and Pipeline Updates\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-11-03 08:12</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>HUTCHMED (00013) announced key updates on its research and business developments during an investor meeting held on October 31, 2025. The event highlighted the company's advancements in innovative therapies for cancer and immune-related diseases, including its next-generation Antibody Targeted Therapeutics Conjugate (ATTC) platform and progress in late-stage pipeline candidates.</p>\n<p>Dr. Shi Ming, Chief Medical Officer and Head of R&D at HUTCHMED, stated, \"Addressing critical unmet medical needs in oncology and immunology remains central to HUTCHMED's mission, driving our commitment to pioneering novel treatments. The ATTC platform has the potential to redefine precision cancer therapy, and with our robust pipeline and collaborative strategy, we are confident in delivering potentially transformative therapies for patients worldwide.\"</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1191","symbol_name":"制药","start_time":0,"source_url":"","article_id":"1174885812","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1174885812","pubTimestamp":1762128739,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"HUTCHMED (00013) announced key updates on its research and business developments during an investor meeting held on October 31, 2025. The event highlighted the company's advancements in innovative...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1191":"制药","00013":"和黄医药","BK4588":"碎股","BK4531":"中概回港概念","BK1587":"次新股","BK1588":"回港中概股","BK4585":"ETF&股票定投概念","BK4007":"制药","HCM":"和黄医药"},"translate_title":"和黄医药(00013)召开投资者见面会分享最新研发进展及管线更新","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00013":1,"HCM":1},"content_text":"HUTCHMED (00013) announced key updates on its research and business developments during an investor meeting held on October 31, 2025. The event highlighted the company's advancements in innovative therapies for cancer and immune-related diseases, including its next-generation Antibody Targeted Therapeutics Conjugate (ATTC) platform and progress in late-stage pipeline candidates.\nDr. Shi Ming, Chief Medical Officer and Head of R&D at HUTCHMED, stated, \"Addressing critical unmet medical needs in oncology and immunology remains central to HUTCHMED's mission, driving our commitment to pioneering novel treatments. The ATTC platform has the potential to redefine precision cancer therapy, and with our robust pipeline and collaborative strategy, we are confident in delivering potentially transformative therapies for patients worldwide.\"","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"conferences","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}